DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 8.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 319,629 shares of the medical device company’s stock after selling 27,695 shares during the period. Bridgewater Associates LP’s holdings in DexCom were worth $21,428,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Taylor Frigon Capital Management LLC increased its holdings in DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the last quarter. Blue Whale Capital LLP grew its stake in shares of DexCom by 91.9% in the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after buying an additional 113,000 shares in the last quarter. Brooktree Capital Management acquired a new stake in shares of DexCom in the third quarter valued at $683,000. National Pension Service raised its holdings in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. acquired a new position in DexCom during the 3rd quarter worth about $650,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Up 0.2 %

DXCM opened at $78.10 on Thursday. The business’s 50-day simple moving average is $71.11 and its 200-day simple moving average is $88.51. The stock has a market capitalization of $30.51 billion, a P/E ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several research reports. JPMorgan Chase & Co. lifted their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Stifel Nicolaus increased their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Wells Fargo & Company raised their price target on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada cut their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.